[Effect of flunixin meglumine on plasma prostanoid concentrations in horses with colic in the perioperative period].
In the present study the significance of eicosanoids in the development of shock in horses on the basis of ileus has been investigated using the prostanoids thromboxane B2 (TXB2) and prostaglandine E2 (PGE2) as indicators. The prostanoid synthesis inhibitor flunixin meglumine was to be examined regarding its efficacy in the effective blockade of the synthesis of these mediators within the peri-operative timeframe as well as its effects on clinical signs and laboratory parameters. 21 horses suffering from ileus and ready for surgical intervention received an intravenous flunixin dosis of 1.1 mg/kg body weight immediately after the initial examination and prior to the surgical procedure. 20 colic horses receiving surgical treatment without application of the drug served as control group. Reference data concerning the approximate standard plasma levels of the prostanoids were determined in 10 healthy horses. Plasma levels of thromboxane B2 and prostaglandine E2 in all colic horses, treatment group as well as controls, initially proved to be significantly higher than the reference values in healthy horses. The untreated control group showed plasma levels highly exceeding the standards within the course of investigation. The application of flunixin meglumine resulted in an effective inhibition of the prostanoid synthesis. Post-operatively as well as within the whole period of investigation the plasma levels of PGE2 and TXB2 of the treated group were considerably lower than those of the control group. Flunixin meglumine had a favorable effect on several cardiovascular parameters. The experimental data concerning the effects of flunixin meglumine thus could be validated in a clinical setting, especially the effective inhibition of the cyclooxygenase enzyme system. The application of the prostanoid synthesis inhibitor flunixin meglumine can be judged as being effective in limiting shock progress in the peri-operative setting given reliable diagnosis.
Gerdemann
R
R
Klinik für Pferde, Tierärztlichen Hochschule Hannover.
Deegen
E
E
Kietzmann
M
M
Venner
M
M
D000818:Animals; D015415:Biomarkers / Q000097:blood; D003002:Clonixin / Q000031:analogs & derivatives* / Q000494:pharmacology; D003085:Colic / Q000097:blood / Q000601:surgery / Q000662:veterinary*; D015232:Dinoprostone / Q000097:blood*; D005260:Female; D006734:Horse Diseases; D006736:Horses; D007415:Intestinal Obstruction / Q000097:blood / Q000601:surgery / Q000662:veterinary*; D008297:Male; D011184:Postoperative Period; D011448:Prostaglandin Antagonists / Q000494:pharmacology*; D013929:Thromboxane B2 / Q000097:blood*
D015415:Biomarkers; D011448:Prostaglandin Antagonists; D013929:Thromboxane B2; C014558:flunixin meglumine; D015232:Dinoprostone; D003002:Clonixin